New appointment

Probiotix Health PLC

29 July 2024

 

29 July 2024

ProBiotix Health plc

("ProBiotix" or the "Company")

New appointment

ProBiotix Health plc (AQUIS: PBX), a life sciences business developing probiotics to support cardiometabolic health, announces it has appointed Cellan Davies as its new Head of Marketing as of 5 July 2024. Cellan's role will be to implement new innovative marketing strategies and enhance customer acquisition efforts.

Through his previous roles with leading global brands such as Lab4 Probiotics by Cultech Ltd and ProVen Probiotics, as well as European companies PRP Supplements and Aliment Nutrition, Cellan has been instrumental in implementing marketing and communication strategies across B2B, B2C and D2C segments within the supplement and nutrition industry. He has worked with ProBiotix for two years in a part time capacity before now transitioning to a fulltime role. He brings more than ten years of commercial and marketing experience in the supplements and nutrition industry, and a specialised focus on probiotics for the past eight years.

Steen Andersen, CEO of ProBiotix Health plc, commented: "We are delighted to have Cellan step into his new role this month, and are already seeing the benefits of his hard work and invaluable experience. As our newly appointed head of marketing, his deep understanding of probiotic science means Cellan is well-equipped to translate complex research into compelling communications for our innovative product portfolio. His energy and passion for probiotic science, combined with his commitment to fostering innovation and driving market expansion strategies, will help to enhance ProBiotix's global market presence."

For further information, please contact:

ProBiotix Health plc	https://probiotixhealth-ir.com/
Steen Andersen, Chief Executive	Contact via Walbrook below
Peterhouse Capital Limited (Aquis Corporate Adviser and Broker)	Tel: [phone]
Mark Anwyl
Duncan Vasey
Walbrook PR Ltd	[e-mail]
Anna Dunphy	Mob: [phone]

About Reach announcements

This is a Reach announcement. Reach is an investor communication service aimed at assisting listed and unlisted (including AIM and AQUIS quoted) companies to distribute media only / non-regulatory news releases into the public domain. Information required to be notified under the AIM Rules for Companies, Market Abuse Regulation or other regulation would be disseminated as an RNS regulatory announcement and not on Reach.

 

END